Developing prognostic biomarkers in intermediate age-related macular degeneration: their clinical use in predicting progression

18Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Age-related macular degeneration is a common, complex and blinding eye disease. When early and intermediate levels of severity are detected in one or both eyes, there is a wide-ranging 0.4 to 53 per cent risk of progression to advanced disease in five years. In order to maximise visual outcomes for their patients, practising eye-care professionals must be able to stratify patients according to their risk of progression, intervene (for example by recommending smoking cessation or nutritional supplements and Amsler grid self-monitoring in intermediate disease) and monitor accordingly. With the aid of ocular imaging, a range of under-recognised yet meaningful risk factors have been identified. The purpose of this review is to assist the eye-care practitioner in stratifying the risk of progression in intermediate age-related macular degeneration using the range of established and emerging precursory signs that herald loss of vision.

Cite

CITATION STYLE

APA

Ly, A., Yapp, M., Nivison-Smith, L., Assaad, N., Hennessy, M., & Kalloniatis, M. (2018, March 1). Developing prognostic biomarkers in intermediate age-related macular degeneration: their clinical use in predicting progression. Clinical and Experimental Optometry. Blackwell Publishing Ltd. https://doi.org/10.1111/cxo.12624

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free